Payment overview · 2025
General Payments
$124.79
6 reported records · 3 companies
Healthcare provider profile · identity verified
Kevin D Sieck, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PAMPA, TX · NPI 1639190770
Verified facts
What the public records show
CMS Open Payments records show Kevin D Sieck, MD received $124.79 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 53.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.42 | 53.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $40.33 | 32.3% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.04 | 14.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.79 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $40.33 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.53 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.89 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 696 | 152 |
| Pantoprazole Sodium | Pantoprazole Sodium | 538 | 128 |
| Atorvastatin Calcium | Atorvastatin Calcium | 468 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 303 | 68 |
| Montelukast Sodium | Montelukast Sodium | 261 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 236 | 54 |
| Omeprazole | Omeprazole | 232 | 54 |
| Tramadol Hcl | Tramadol Hcl | 232 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 218 | 51 |
| Gabapentin | Gabapentin | 216 | 57 |
| Losartan Potassium | Losartan Potassium | 216 | 56 |
| Allopurinol | Allopurinol | 214 | 47 |
| Lisinopril | Lisinopril | 213 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 212 | 40 |
| Metformin Hcl | Metformin Hcl | 203 | 58 |
| Potassium Chloride | Potassium Chloride | 203 | 48 |
| Alprazolam | Alprazolam | 183 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 181 | 53 |
| Furosemide | Furosemide | 179 | 41 |
| Carvedilol | Carvedilol | 160 | 41 |
| Meloxicam | Meloxicam | 154 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 150 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 38 |
| Glimepiride | Glimepiride | 128 | 29 |
| Eliquis | Apixaban | 116 | 23 |
| Lorazepam | Lorazepam | 109 | 18 |
| Celecoxib | Celecoxib | 108 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 22 |
| Ramipril | Ramipril | 95 | 22 |
| Donepezil Hcl | Donepezil Hcl | 94 | 20 |
| Jardiance | Empagliflozin | 88 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 13 |
| Clonazepam | Clonazepam | 86 | 15 |
| Trazodone Hcl | Trazodone Hcl | 83 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 17 |
| Sertraline Hcl | Sertraline Hcl | 78 | 19 |
| Simvastatin | Simvastatin | 69 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 13 |
| Pregabalin | Pregabalin | 66 | 15 |
| Finasteride | Finasteride | 62 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 61 | 14 |
| Ozempic | Semaglutide | 61 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 15 |
| Azithromycin | Azithromycin | 58 | 49 |
| Mounjaro | Tirzepatide | 57 | 11 |
| Amoxicillin | Amoxicillin | 56 | 34 |
| Rybelsus | Semaglutide | 56 | suppressed |
| Ezetimibe | Ezetimibe | 54 | 11 |
| Methocarbamol | Methocarbamol | 54 | 11 |
| Spironolactone | Spironolactone | 54 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 30 |
| Estradiol | Estradiol | 50 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | suppressed |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 34 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | suppressed |
| Topiramate | Topiramate | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 33 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 43 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Temazepam | Temazepam | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Irbesartan | Irbesartan | 39 | 11 |
| Chlorthalidone | Chlorthalidone | 38 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Prednisone | Prednisone | 37 | 16 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 20 |
| Trintellix | Vortioxetine Hydrobromide | 36 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 12 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 25 |
| Fluconazole | Fluconazole | 31 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 16 |
| Tradjenta | Linagliptin | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 12 |
| Ondansetron Odt | Ondansetron | 22 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 15 |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Prolia | Denosumab | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.79 · 6 records | ABBVIE INC. | ABRE, LEQVIO, QULIPTA, UBRELVY, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error